UK markets closed
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • FTSE 250

    22,537.89
    -742.07 (-3.19%)
     
  • AIM

    1,181.62
    -22.34 (-1.86%)
     
  • GBP/EUR

    1.1779
    -0.0100 (-0.84%)
     
  • GBP/USD

    1.3342
    +0.0022 (+0.16%)
     
  • BTC-GBP

    40,752.80
    -181.45 (-0.44%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • DOW

    34,899.34
    -905.04 (-2.53%)
     
  • CRUDE OIL

    68.15
    -10.24 (-13.06%)
     
  • GOLD FUTURES

    1,788.10
    +1.20 (+0.07%)
     
  • NIKKEI 225

    28,751.62
    -747.66 (-2.53%)
     
  • HANG SENG

    24,080.52
    -659.64 (-2.67%)
     
  • DAX

    15,257.04
    -660.94 (-4.15%)
     
  • CAC 40

    6,739.73
    -336.14 (-4.75%)
     

Evotec SE reports results for the first nine months 2021 and provides corporate update

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·6-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: Evotec SE / Key word(s): 9 Month figures
11.11.2021 / 07:01
The issuer is solely responsible for the content of this announcement.

 

Hamburg, Germany, 11 November 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2021.
 

HIGHLIGHTS

STRONG REVENUES GROWTH IN ALL BUSINESS AREAS FUELS ONGOING EXPANSION AND STRENGTHENS POSITIVE DEVELOPMENT


DATA-DRIVEN AUTOBAHN TO CURES: STRONG PROGRESS IN ALL LANES

CORPORATE


CONFIRMATION OF BUSINESS OUTLOOK FOR FULL-YEAR 2021 AND MID-TERM TARGETS 2025


Given current global insecurities surrounding the COVID-19 pandemic, a likely negative impact - though less pronounced than in 2020 - is already estimated within the guidance for revenues and adjusted EBITDA stated above.

More detailed information and financial tables are available in our nine-month report published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/publications

 

FINANCIAL HIGHLIGHTS

The following table provides an overview of the financial performance in the first nine months of 2021 compared to the same period in 2020.

Key figures of consolidated income statement & segment information>
Evotec SE & subsidiaries - First nine months of 2021



In T€


EVT
Execute4)


EVT
Innovate5)


Intersegment Eliminations

Evotec Group
9M 2021

Evotec Group
9M 2020

External revenues1)

329,023

101,940

-

430,963

360,414

Intersegment revenues

100,751

-

(100,751)

-

-

Costs of revenues

(343,418)

(79,781)

91,705

(331,494)

(271.225)

Gross profit

86,356

22,159

(9,046)

99,469

89,189

Gross margin in %

20.1

21.7

-

23.1

24.7

 

 

 

 

 

 

R&D expenses2)

(2,120)

(60,398)

9,046

(53,472)

(46,077)

SG&A expenses

(56,714)

(14,323)

-

(71,037)

(58,132)

Impairments of intangible assets and goodwill


-


(683)


-


(683)


-

Other operating
income (expenses), net


17,539


34,237

-


51,776


50,306

Operating result

45,061

(19,008)

-

26,053

35,286

 

 

 

 

 

 

Adjusted EBITDA3)

85,985

(15,899)

-

70,086

76,942

1) Adjusted for negative exchange rate effects of € 11.2 m, Group revenues amount to € 442.1 m
2) Of which unpartnered R&D expenses of €
42.6 m in 9M 2021 (9M 2020: € 33.4 m)
3) Before changes in contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
4) Revenues from material recharges of €
23.6 m are allocated to EVT Execute as of 9M 2021
5) Revenues from material recharges of € 1.2m are allocated to EVT Innovate as of 9M 2021

 

WEBCAST / CONFERENCE CALL

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Conference call details
Date: Thursday, 11 November 2021
Time: 02.00 pm CET (08.00 am ET, 01.00 pm GMT)

From Germany: +49 69 20 17 44 220
From France: +33 170 709 502
From Italy: +39 023 600 6663
From Switzerland: +41 445 806 522
From UK: +44 20 3009 2470
From USA: +1 877 423 0830
Access Code: 82123163#

A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec20211111/no-audio.


Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our homepage http://www.evotec.com shortly before the event.

A replay of the conference call will be available for seven days and can be accessed from Germany by dialling +49 69 201744221, from UK by dialling +44 20 3364 5150 and from USA by dialling +1 (844) 307-9362.

The access code is 315614529#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/en/investor-relations/publications and under the direct link https://www.webcast-eqs.com/evotec20211111.



ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.



IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com
 


11.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Evotec SE

Manfred Eigen Campus / Essener Bogen 7

22419 Hamburg

Germany

Phone:

+49 (0)40 560 81-0

Fax:

+49 (0)40 560 81-222

E-mail:

info@evotec.com

Internet:

www.evotec.com

ISIN:

DE0005664809

WKN:

566480

Indices:

MDAX, TecDAX

Listed:

Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq

EQS News ID:

1248088


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting